IP Library Granted Patent US 9,637,551
Granted Patent B2
US 9,637,551 · App. 12/636,655 · Granted May 2, 2017

Multi-component inhibitors of nucleic acid polymerases

Inventors: John D. Bishop (Carlsbad, CA); Jun E. Lee (San Diego, CA)
Assignee: LIFE TECHNOLOGIES CORPORATION
C07K16/40C12Q1/6848
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,637,551
App. No.
12/636,655
Granted
May 2, 2017
Kind
B2
Abstract

The present invention provides multi-component inhibitors of nucleic acid polymerases, methods of making, and methods of using same. One component of the multi-component inhibitor is a molecule that binds to a polymerase (i.e., a polymerase-binding molecule (PBM)), but does not thereby substantially inhibit its polymerase activity. Another component is a molecule or complex of molecules that binds to a PBM (i.e., a PBM-binding molecule). The combination of the PBM and PBM-binding molecule/complex substantially inhibits polymerase activity.

Claims (16)

1. A composition comprising:

(a) a thermostable DNA polymerase, wherein said thermostable DNA polymerase is selected from the group consisting of: Thermus aquaticus (Taq) DNA polymerase, Thermus filiformis (Tfi) DNA polymerase, and Thermococcus zilligi (Tzi) DNA polymerase; and

(b) a primary monoclonal antibody that binds to said polymerase, and

(c) a secondary anti-IgG polyclonal antibody that binds to said primary antibody,

wherein said primary antibody alone, when bound to said polymerase, inhibits polymerase activity by 10% or less,

and wherein said primary antibody in complex with said secondary antibody, when bound to said polymerase, inhibits polymerase activity by 90% or more.

2. The composition of claim 1 , wherein said inhibition of said polymerase by said primary antibody with said secondary antibody is reversible.

3. The composition of claim 2 , wherein said inhibition of said polymerase by said primary antibody with said secondary antibody is reversible by heating to a temperature of at least 40° C.

4. The composition of claim 1 , wherein said primary and/or said secondary antibody is a derivatized antibody.

5. The composition of claim 1 , wherein said primary antibody and/or said secondary antibody is detectably labeled.

6. The composition of claim 5 , wherein said primary antibody and/or said secondary antibody is detectably labeled with horseradish peroxidase (HRP), rhodamine, biotin, fluorescein, alkaline phosphatase, or AlexaFluor488.

7. The composition of claim 1 , wherein said composition further comprises one or more nucleoside triphosphates and/or deoxynucleoside triphosphates.

8. The composition of claim 1 , wherein said Taq, Tfi or Tzi DNA polymerase is recombinant.

9. The composition of claim 1 , wherein said secondary antibody is coupled with a protein or polymer.

10. The composition of claim 9 , wherein said protein is horseradish peroxidase, alkaline phosphatase, or albumin.

11. The composition of claim 9 , wherein said polymer is a polyethylene glycol, a polyoxyethylene, a polyoxypropylene, or a polyoxyethylene/polyoxypropylene copolymer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2009
From: BISHOP, JOHN D.; LEE, JUN E.
To: INVITROGEN CORPORATION
Reel/Frame 023645/0106 →
CHANGE OF NAME Recorded Dec 12, 2009
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 023645/0113 →
Continuity (3)
Continuation 11341870 · Jan 30, 2006
Continuation In Part 11044620 · Jan 28, 2005
Related Publication 20100209975A1 · Aug 19, 2010